Commencement of Share Buyback Extension
Source: RNS
Centrica plc
8 August 2024
Commencement of Share Buyback Extension
As set out with its 2024 Interim Results on 25th July 2024, Centrica plc (the "Company") announces the commencement of a £200 million extension of the Company's share repurchase programme to be completed by the end of February 2025 ("the Extension").
Since 15 November 2022 the Company has repurchased approximately £1 billion of its ordinary shares, representing almost 14% of the Company's issued share capital at that date.
For the Extension, the Company has entered into an irrevocable arrangement with Goldman Sachs International (acting as riskless principal) to conduct the share repurchases on its behalf and to make trading decisions in respect of the Extension independently of the Company.
The arrangement with Goldman Sachs International enables the purchase of ordinary shares for a period from 8 August 2024 up to and including 28 February 2025. The aggregate maximum consideration for the purchase of ordinary shares under the Extension is £200 million (exclusive of associated fees, expenses and stamp duty). Goldman Sachs International may effect purchases of shares under the Extension on the London Stock Exchange and/or other trading venues for subsequent purchase by the Company. Purchases by the Company will be treated as being made on the London Stock Exchange. The Company intends that any shares purchased will be cancelled, held in treasury, or used for the purposes of employee share schemes.
The purpose of the Extension is to reduce the capital of the Company.
Any share purchase will be carried out in accordance with certain pre-set parameters. The maximum number of ordinary shares which may be purchased by the Company under the Extension is 536,039,506 which is the maximum pursuant to the authority granted by shareholders at the Company's 2024 Annual General Meeting.
The Extension will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014/EU (as in force in the UK and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019), the Commission Delegated Regulation 2016/1052/EU (as in force in the UK and as amended by the FCA's Technical Standards (Market Abuse Regulation) (EU Exit) Instrument 2019) and in accordance with Chapter 9 of the UK Listing Rules. No repurchases will be made in respect of the Company's American Depositary Receipts.
The Company will make further announcements in due course following any repurchase of shares. There is no guarantee that the Extension will be implemented in full or that any shares will be bought back by the Company.
Enquiries:
Investors and Analysts
T: 01753 494900
E: ir@centrica.com
Media
T: 01784 843000
E: media@centrica.com
END
Centrica plc is listed on the London Stock Exchange (CNA)
Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD
Registered in England & Wales number: 3033654
Legal Entity Identifier number: E26EDV109X6EEPBKVH76
ISIN number: GB00B033F229
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.